During the last two decades, development of anti-HER2 therapies has significantly improved the prognosis of patients with HER2-positive (HER2+) breast cancer both at early and metastatic disease stages5; however, some patient populations demonstrate clinical resistance to anti-HER2 therapies6. This evidence concerns the gene ERBB2 and breast carcinoma.